Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company VetbiolixRamat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite ...
Nasdaq

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch ...
Hosted on MSN

Can-Fite BioPharma shares surged 50% in pre-market on Brazilian patent win

・Can-Fite is advancing its proprietary A3AR agonist platform across multiple indications, including oncology and inflammatory diseases. ・The new patent expands Can-Fite’s IP coverage in Brazil and ...
Seeking Alpha

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF) (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule ...
Business Insider

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small ...
Nasdaq

Can-Fite BioPharma Announces FDA Approval for Compassionate Use of Namodenoson in Pancreatic Cancer Patient

Can-Fite BioPharma Ltd. has announced FDA approval for compassionate use of its anti-cancer drug Namodenoson for a U.S. pancreatic cancer patient. This approval allows the physician to provide the ...

Can-Fite BioPharma Ltd.: Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biote ...